Jefferies Upgrades PTC Therapeutics to Buy, Raises Price Target to $85
Benzinga Newsdesk 5 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Jefferies analyst Faisal Khurshid upgrades PTC Therapeutics (NASDAQ:PTCT) from Hold to Buy and raises the price target from $76 to $85.
Jefferies analyst Faisal Khurshid upgrades PTC Therapeutics (NASDAQ:PTCT) from Hold to Buy and raises the price target from $76 to $85.